News articles about Advaxis (NASDAQ:ADXS) have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Advaxis earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.5330849659252 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
A number of equities analysts have commented on ADXS shares. HC Wainwright set a $23.00 price target on shares of Advaxis and gave the stock a “buy” rating in a research note on Wednesday, December 27th. Cantor Fitzgerald set a $19.00 price target on shares of Advaxis and gave the stock a “buy” rating in a research note on Thursday, December 28th. Finally, ValuEngine cut shares of Advaxis from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 3rd.
Advaxis (ADXS) traded down $0.07 during mid-day trading on Wednesday, reaching $2.96. 684,018 shares of the company’s stock were exchanged, compared to its average volume of 1,020,000. Advaxis has a fifty-two week low of $2.71 and a fifty-two week high of $10.06. The stock has a market cap of $121.55, a PE ratio of -1.29 and a beta of 1.91.
Advaxis (NASDAQ:ADXS) last announced its quarterly earnings data on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.02). Advaxis had a negative net margin of 776.63% and a negative return on equity of 114.00%. The business had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $3.05 million. analysts anticipate that Advaxis will post -2.36 earnings per share for the current year.
In related news, CFO Sara Bonstein sold 12,734 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total transaction of $40,621.46. Following the completion of the sale, the chief financial officer now directly owns 244,504 shares in the company, valued at approximately $779,967.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Robert Petit sold 12,625 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total transaction of $40,273.75. Following the sale, the insider now owns 237,265 shares of the company’s stock, valued at $756,875.35. The disclosure for this sale can be found here. Insiders sold a total of 38,192 shares of company stock valued at $122,615 in the last ninety days. 7.21% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/31/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-advaxis-adxs-share-price.html.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.